COVID-19: Vaccines and Therapeutics
Moderna announced an updated timeline for its COVID-19 vaccine for children. According to Moderna, the Food and Drug Administration last week notified the drug maker that it may not complete its assessment of the company’s EUA request for children age 12 to 17 before January 2022.
The recent expansion of COVID-19 booster shots for certain adult Americans means that millions more people are now eligible to seek extra protection against the deadly virus.
The Food and Drug Administration authorized Pfizer’s COVID-19 vaccine for pediatric use, moving the issue of administration to the Centers for Disease Control and Prevention for consideration.
The American Medical Association published a Current Procedural Terminology code for providers administering a booster dose of the Johnson & Johnson COVID-19 vaccine.
In a study of over 7,000 adults hospitalized with COVID-19 symptoms, unvaccinated patients with prior SARS-CoV-2 infection were five times more likely to have laboratory-confirmed COVID-19 than were patients fully vaccinated against COVID-19 and no previous infection, the Centers for Disease…
Pediatricians join the front lines of COVID-19 vaccination plans as eligibility expands to children 5 to 11 years old.
Connecticut Children’s is sharing information to help parents prepare their children for the COVID-19 vaccine, once authorized for ages 5-11.
As a Centers for Disease Control and Prevention advisory committee prepares to consider expanding COVID-19 vaccine eligibility to children aged 5-11, the AHA, American Academy of Pediatrics and Children’s Hospital Association will webcast a panel discussion Nov. 8 at 2 p.m. ET on how pediatricians…
Please join the American Hospital Association, the American Academy of Pediatrics and the Children’s Hospital Association as pediatricians and hospital leaders discuss how doctors can work with parents to build trust in the safety and efficacy of COVID-19 vaccines for children, and offer key…
In a study comparing 6.4 million COVID-19 vaccine recipients with 4.6 million demographically similar unvaccinated persons, recipients of the Pfizer, Moderna or Janssen vaccines had lower non-COVID-19 mortality risk than did the unvaccinated comparison groups, the Centers for Disease Control and…